Covenant by ABX Sample Clauses

Covenant by ABX. With respect to each Failed Antigen, neither ABX nor its Affiliates will independently sell or offer for sale, or enter into an agreement with, or grant any license to, a Third Party to sell or offer for sale or otherwise Exploit, any Antibodies or Antibody Equivalents that bind to and are directed against such Failed Antigen for a period of [Confidential treatment requested] after the date that such Antigen was designated as a Failed Antigen. If, at any time during such [Confidential treatment requested] period, ABX wishes to independently perform work with respect to such Failed Antigen, ABX shall provide written notice to AZ. ABX shall provide AZ with any Information, Antibodies, Antibody Equivalents and other materials generated in connection with such work on a quarterly basis and, at the end of such [Confidential treatment requested] period, ABX shall provide AZ with a final report on all work it has performed with respect to such Failed Antigen and such Information and materials as AZ may reasonably request. Upon receipt of such report, Information and materials, AZ shall have the right, for a period of [Confidential treatment requested], to designate such Antigen as a Collaboration Antigen under the terms set forth herein, regardless of the number of Collaboration Antigens that have been designated as of such date or whether the Antigen Designation Term has expired. If such Antigen is designated as a Collaboration Antigen pursuant to the foregoing sentence, any such work performed by ABX during such one (1) year period shall be deemed to have been performed under the Research Program for such Collaboration Antigen and the provisions of Sections 11.1.1, 11.1.3, 11.1.4, 11.1.5 and 11.1.7 shall apply. If such Antigen is not designated as a Collaboration Antigen, then all Information and inventions conceived or generated in connection with any such work performed by ABX during such [Confidential treatment requested] period that would have been Collaboration Technology if such work had been performed under a Research Program shall be Collaboration Technology and the provisions of Section 11.1.3 shall apply thereto. If AZ declines to designate such Antigen as a Collaboration Antigen, AZ shall notify ABX in writing and, if ABX wishes to pursue Antibodies or Antibody Equivalents that bind to and are directed against such Antigen, ABX shall provide an Exercise Notice to AZ and such Antigen shall be designated a Discontinued Antigen, but only with respect to...
AutoNDA by SimpleDocs
Covenant by ABX. During the term of this Agreement, ABX and its Affiliates shall not, and shall not grant any license or right to any Third Party under the Licensed ABX IP Rights to, Exploit Antibody Equivalents that bind to and are directed against, or any other products with respect to, a Collaboration Antigen with respect to which AZ has timely delivered, or still has the right to deliver, an Election Notice to ABX pursuant to Section 5.9. Any grant of any such license or right by ABX shall be void ab initio and of no force and effect. Any breach of this Section 4.3.3 shall be a material breach of a material obligation of ABX and shall give rise to the right to terminate under Section 16.3, which right shall be in addition to any other rights and remedies that may be available.
Covenant by ABX. During the term of this Agreement, ABX and its Affiliates shall not, and shall not grant any license or right to any Third Party under the Licensed ABX IP Rights to, Exploit Antibody Equivalents that bind to and are directed against, or any other products with respect to, a Collaboration Antigen with respect to which AZ has timely delivered, or still has the right to deliver, an Election Notice to ABX pursuant to

Related to Covenant by ABX

  • Covenants by Executive 5.1 As of the Effective Date, Executive is a party to the Proprietary Information and Additional Covenants Agreement between Executive and Forge (the “PICA”). Subject to § 5.9 below, Executive shall comply with all applicable terms and conditions of the PICA throughout the Term hereof, and hereby agrees to execute and comply with any amendments to or updated versions of the PICA that Forge may require of its officers and employees from time to time. Future amendments or updated versions will be automatically incorporated into this Employment Agreement upon execution thereof and will revise or replace the previous PICA, each such amended or new version of the PICA subject to § 5.9 below, and all references to “PICA” in this Employment Agreement will be interpreted as referring to the then-current version of the PICA executed by the Executive; provided, however, references to “PICA” in § 4.2(c)(4) shall refer to the PICA in effect on the date hereof or any subsequent form of the PICA which Executive explicitly agrees to incorporate into § 4.2(c)(4). Capitalized terms used in this § 5 but not defined in this Employment Agreement will have the meaning provided in the PICA. If there is a conflict between this § 5 and the PICA, this § 5 will control but only with respect to the conflicting provisions and to the extent necessary to resolve the conflict.

  • Assignment by Executive This Agreement shall inure to the benefit of and be enforceable by the Executive's executor and/or administrators, heirs, devisees, and legatees. If the Executive should die while any amount would be payable to Executive hereunder had the Executive continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the Executive's estate. Executive's rights hereunder shall not otherwise be assignable.

  • Representations by Executive Executive warrants that Executive is legally competent to execute this Agreement and that Executive has not relied on any statements or explanations made by the Company or its attorneys. Executive acknowledges that Executive has been afforded the opportunity to be advised by legal counsel regarding the terms of this Agreement, including the Release. Executive acknowledges that Executive has been offered at least 21 days to consider this Agreement. After being so advised, and without coercion of any kind, Executive freely, knowingly, and voluntarily enters into this Agreement. Executive acknowledges that Executive may revoke this Agreement within seven days after Executive has signed this Agreement and acknowledges understanding that this Agreement shall not become effective or enforceable until seven days after Executive has signed this Agreement (the “Effective Date”), as evidenced by the date set forth below Executive’s signature on the signature page hereto. Any revocation must be in writing and directed to [_______________]. If sent by mail, any revocation must be postmarked within the seven-day period described above and sent by certified mail, return receipt requested.

  • No Assignment by Executive Executive warrants and represents that no portion of any of the matters released herein, and no portion of any recovery or settlement to which Executive might be entitled, has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Company or any other Releasee because of any actual assignment, subrogation or transfer by Executive, Executive agrees to indemnify and hold harmless the Company and all other Releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. In the event of Executive’s death, this Agreement shall inure to the benefit of Executive and Executive’s executors, administrators, heirs, distributees, devisees, and legatees. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only upon Executive’s death by will or operation of law.

  • Representation by Executive Executive hereby represents and warrants to Company that, as of the Effective Date, he is not party to any employment or other agreement or obligation with or to any third party which would preclude him from employment with Company and performing his obligations under this Agreement.

  • Assistance by Executive During the period of Executive’s employment by Company and thereafter, Executive shall assist Company and its nominee, at any time, in the protection of Company’s (or its affiliates’) worldwide right, title and interest in and to Work Product and the execution of all formal assignment documents requested by Company or its nominee and the execution of all lawful oaths and applications for patents and registration of copyright in the United States and foreign countries.

  • Acknowledgment by Executive The Executive acknowledges and confirms that (a) the restrictive covenants contained in this Article 6 are reasonably necessary to protect the legitimate business interests of the Company, and (b) the restrictions contained in this Article 6 (including without limitation the length of the term of the provisions of this Article 6) are not overbroad, overlong, or unfair and are not the result of overreaching, duress or coercion of any kind. The Executive further acknowledges and confirms that his full, uninhibited and faithful observance of each of the covenants contained in this Article 6 will not cause him any undue hardship, financial or otherwise, and that enforcement of each of the covenants contained herein will not impair his ability to obtain employment commensurate with his abilities and on terms fully acceptable to him or otherwise to obtain income required for the comfortable support of him and his family and the satisfaction of the needs of his creditors. The Executive acknowledges and confirms that his special knowledge of the business of the Company is such as would cause the Company serious injury or loss if he were to use such ability and knowledge to the benefit of a competitor or were to compete with the Company in violation of the terms of this Article 6. The Executive further acknowledges that the restrictions contained in this Article 6 are intended to be, and shall be, for the benefit of and shall be enforceable by, the Company’s successors and assigns.

  • Covenants of the Executive In consideration of the acknowledgments by the Executive, and in consideration of the compensation and benefits to be paid or provided to the Executive by the Employer, the Executive covenants that he will not, directly or indirectly:

  • Covenant Breaches The Borrower, any Guarantor or any of their respective Subsidiaries shall fail to (i) perform or observe any covenant contained in Section 5.02(a), Section 5.03, Section 5.06(e), Section 5.09, Section 5.12, or Article VI of this Agreement or (ii) fail to perform or observe any other term or covenant set forth in this Agreement or in any other Loan Document which is not covered by clause (i) above or any other provision of this Section 7.01 if such failure shall remain unremedied for 30 days after the occurrence of such breach or failure;

  • Representations and Warranties by Executive The Executive represents and warrants that he is not a party to or subject to any restrictive covenants, legal restrictions or other agreements in favor of any entity or person which would in any way preclude, inhibit, impair or limit the Executive’s ability to perform his obligations under this Agreement, including, but not limited to, non-competition agreements, non-solicitation agreements or confidentiality agreements.

Time is Money Join Law Insider Premium to draft better contracts faster.